Hilton London Docklands Riverside Hotel , London, UK
Apr 24 2012 1:00PM - Apr 26 2012 5:30PM
This year’s conference’s focuses on the new EU pharmacovigilance legislation and on its potential impact on the EU QPPV. The opening session will explore the practical challenges of implementation, some legal aspects and explain how the new Committees and Procedures will impact how we work. The sessions that follow include: • QUALITY MATTERS QPPVs will receive the latest information on the development of PSMFs, some practical advice on implementing quality systems in PV and an update on findings of interest from recent inspections. • MANAGING THE ‘HOUSE OF CARDS’: HOW TO COPE WITH GLOBALISATION AND TECHNOLOGY Hear the latest tips and share experiences. • CURRENT TRENDS This session will explore the challenges posed and opportunities presented for pharmacovigilance by new technologies such as social media. • EU LEGISLATION: STRONGER, MORE EFFICIENT AND MORE TRANSPARENT? BUT WHERE DOES THE QPPV FIT IN? Put your questions to an expert panel. • MOVING FROM SAFETY REPORTING TO BENEFIT: RISK EVALUATION An overview of the main changes in and insights on benefit/ risk and signal detection activities. • BENEFIT/RISK MANAGEMENT Regulators and industry reveal how the science of post-authorisation effectiveness measurement has progressed and its impact on the QPPV's oversight of the pharmacovigilance system. • CHALLENGES OF CHANGING LEGISLATION ON OVERSIGHT ROLE OF THE QPPV - Receive specific examples of current divergence in expectation at the national level - Discuss how a QPPV can best monitor for and address any varying expectations as the upcoming implementation progresses - Explore whether or not the QPPV will need new skills/training in the new world.
Event Code: 12104
|